Ivuxolimab is an CD4+ and CD8+ T cells. Ivuxolimab shows antitumor activity, with potential immunostimulatory activity[1].
[1]. Diab A, et al. A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. Clin Cancer Res. 2022 Jan 1;28(1):71-83.
















